Your browser doesn't support javascript.
loading
Cognitive and other neuropsychiatric symptoms in COVID-19: analysis of person-generated longitudinal health data from a community-based registry.
Largent, Joan; Xie, Yiqiong; Knuth, Kendall B; Toovey, Stephen; Reynolds, Matthew W; Brinkley, Emma; Mack, Christina D; Dreyer, Nancy A.
Affiliation
  • Largent J; Real World Solutions, IQVIA Inc, Durham, North Carolina, USA.
  • Xie Y; Real World Solutions, IQVIA Inc, Durham, Massachusetts, USA.
  • Knuth KB; Real World Solutions, IQVIA Inc, Durham, North Carolina, USA.
  • Toovey S; Virology, Pegasus Research, Bottmingen, Switzerland.
  • Reynolds MW; Real World Solutions, IQVIA Inc, Durham, North Carolina, USA.
  • Brinkley E; Real World Solutions, IQVIA Inc, Durham, North Carolina, USA.
  • Mack CD; Real World Solutions, IQVIA Inc, Durham, North Carolina, USA.
  • Dreyer NA; Real World Solutions, IQVIA Inc, Durham, North Carolina, USA NDreyer@dreyerstrategies.com.
BMJ Open ; 13(6): e069118, 2023 06 19.
Article in En | MEDLINE | ID: mdl-37336535
OBJECTIVE: To describe cognitive symptoms in people not hospitalised at study enrolment for SARS-CoV-2 infection and associated demographics, medical history, other neuropsychiatric symptoms and SARS-CoV-2 vaccination. DESIGN: Longitudinal observational study. SETTING: Direct-to-participant registry with community-based recruitment via email and social media including Google, Facebook and Reddit, targeting adult US residents. Demographics, medical history, COVID-19-like symptoms, tests and vaccinations were collected through enrolment and follow-up surveys. PARTICIPANTS: Participants who reported positive COVID-19 test results between 15 December 2020 and 13 December 2021. Those with cognitive symptoms were compared with those not reporting such symptoms. MAIN OUTCOME MEASURE: Self-reported cognitive symptoms (defined as 'feeling disoriented or having trouble thinking' from listed options or related written-in symptoms) RESULTS: Of 3908 participants with a positive COVID-19 test result, 1014 (25.9%) reported cognitive symptoms at any time point during enrolment or follow-up, with approximately half reporting moderate/severe symptoms. Cognitive symptoms were associated with other neuropsychiatric symptoms, including dysgeusia, anosmia, trouble waking up, insomnia, headache, anxiety and depression. In multivariate analyses, female sex (OR, 95% CI): 1.7 (1.3 to 2.2), age (40-49 years (OR: 1.5 (1.2-1.9) compared with 18-29 years), history of autoimmune disease (OR: 1.5 (1.2-2.1)), lung disease (OR: 1.7 (1.3-2.2)) and depression (OR: 1.4 (1.1-1.7)) were associated with cognitive symptoms. Conversely, black race (OR: 0.6 (0.5-0.9)) and COVID-19 vaccination before infection (OR: 0.6 (0.4-0.7)) were associated with reduced occurrence of cognitive symptoms. CONCLUSIONS: In this study, cognitive symptoms among COVID-19-positive participants were associated with female gender, age, autoimmune disorders, lung disease and depression. Vaccination and black race were associated with lower occurrence of cognitive symptoms. A constellation of neuropsychiatric and psychological symptoms occurred with cognitive symptoms. Our findings suggest COVID-19's full health and economic burden may be underestimated. TRIAL REGISTRATION NUMBER: NCT04368065.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Type of study: Diagnostic_studies / Observational_studies / Risk_factors_studies Limits: Adult / Female / Humans / Middle aged Language: En Journal: BMJ Open Year: 2023 Document type: Article Affiliation country: United States Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Type of study: Diagnostic_studies / Observational_studies / Risk_factors_studies Limits: Adult / Female / Humans / Middle aged Language: En Journal: BMJ Open Year: 2023 Document type: Article Affiliation country: United States Country of publication: United kingdom